

	1	EDWGPCTEHG	EHNIKIPITP	ARVTGGYRLV	DKIPIHNTTES	RLVDFSPQPS	RGSTRYSWPK	FAVPILQSLT	ILLSSNLSWL	SLDYSAAPYH	ILPHPAAMPH	LLVGESGLPR	YVARLSSTSR	120
Sample 1		YR												
Sample 1													G	
Sample 1		R												
Sample 1		R										F		
Sample 2														
Sample 2														
Sample 2	D													
Sample 2														
Sample 3														I
Sample 3		R												I
Sample 3							A							I
Sample 3		R												I
Sample 4														V
Sample 4														I
Sample 4						G Y								V
Sample 4														V
Sample 5														V
Sample 5														V
Sample 5														V
Sample 5	R						K K H I							V
Sample 5														V

	121	NBYQHGTMQ	NLHNECSRNL	YVSLLLYKT	FGRIKULFESH	PIILGFRKIP	HGVGLSPILL	AQFITSALCV	VRRAPFHCLA	PSYMDDVILG	AKSVQHLESIL	FTSITNRLLS	LGDIHLNPKIT	240
Sample 1		D				Y							YAAV	
Sample 1		D				Y							YAAV H	
Sample 1		D				Y							YAAV	
Sample 1		D				Y							YAAV	
Sample 2	D					Y							YAAV H	
Sample 2	Q					Y							YAAV H	
Sample 2	D					Y							YAAV	
Sample 2	D					Y							YAAV	
Sample 3	D					Y							YAAV	I
Sample 3	D					Y							YAAV	I
Sample 3	D					Y			G				YAAV	V
Sample 3	D					Y							YAAV	I
Sample 4	D					Y			M				YAAV	I
Sample 4	D					Y			S				YAAV	I
Sample 4	D					Y			M				YAAV	V
Sample 4	D					Y							YAAV	I
Sample 5	D					Y			M				YAAV	V
Sample 5	D					Y			M				YAAV	V
Sample 5	D					Y			M				YAAV	V
Sample 5	D					Y							YAAV	V

Figure 3 Comparison of amino acid sequences of HBV polymerase gene of isolates before lamivudine treatment (sample 1) and four sequential isolates (samples 2-5) during treatment. A HBV mutant with substitutions of isoleucine for leucine at residue 80 (rtL80I) in combination with isoleucine for methionine at residue 204 (rtM204I) was observed 12 mo after treatment (sample 3). After vidarabine treatment, another HBV mutant with substitutions of valine for leucine at residue 80 (rtL80V) and valine for methionine at residue 204 (rtM204V) was observed (sample 4). These mutations predominated in combination with methionine for leucine at residue 180 (rtL180M) after interferon treatment (sample 5). The published HBV DNA sequence of hepatitis B virus variant (genotype C, AB033550, Okamoto *et al.*^[36]) was used for comparison.

the condition of the patient, rtL180M, rtM204I/V and rtL80I/V became predominant. Natsuzaka *et al.*^[25] showed that rtL180M and rtM204V are related to the exacerbation of hepatitis. Interestingly, a patient with a marked elevation in HBV DNA level in Ogata's report had rtL180M in addition to rtL80I and rtM204I. Therefore, the acquisitions of rtL80I/V and rtL180M in addition to rtM204I/V may be associated with a severe exacerbation of hepatitis. Large-scale studies are necessary to elucidate this hypothesis.

In our patient, vidarabine decreased HBV DNA levels and improved liver function. Although the long-term use of vidarabine is contraindicated because of its possible side effects including irreversible neurotoxicity^[22], its short-term use is effective for controlling active HBV infection and herpes simplex viral infection.

Vidarabine was replaced by interferon- α because adefovir dipivoxil was not available in 2002. Serum HBV DNA and bilirubin levels increased again, which led to a fatal outcome, and HBV clones that have rtL180M became predominant, indicating that withdrawal of vidarabine and administration of interferon may be dangerous for the treatment of severe breakthrough hepatitis. Since interferon may potentially precipitate immunological flares and liver failure^[20], nucleoside analogues that are effective for lamivudine-resistant HBV such as adefovir dipivoxil^[30-32], entecavir^[33-35] and tenofovir^[36,37], should be used for the treatment of severe breakthrough hepatitis instead of vidarabine or interferon.

In conclusion, antiviral therapy should be considered in the treatment of patients with hepatic failure after

breakthrough hepatitis caused by HBV mutants to lamivudine. The serial acquisition of amino acid mutations outside the YMDD motif in the polymerase region may be associated with severe hepatitis.

REFERENCES

- Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. *Hepatology* 2004; **39**: 857-861
- Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Kane E, Kao JH, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. *Liver Int* 2005; **25**: 472-489
- Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. *Hepatology* 2000; **31**: 207-210
- Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. *J Hepatol* 2000; **33**: 301-307
- Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, Hasnain SE, Sarin SK. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. *J Hepatol* 2000; **33**: 308-312
- Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. *Liver Transpl* 2000; **6**: 715-720
- Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, Soldevila-Pico C, McClure LA, Lok AS. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. *Liver Transpl* 2002; **8**: 433-439
- Yao FY, Terrault NA, Freise C, Maslow L, Bass NM.

- Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. *Hepatology* 2001; **34**: 411-416
- 9 Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Gardner SD, Brown N, Griffiths D. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. *Liver Transpl* 2003; **9**: 49-56
 - 10 Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D, Avgerinos A. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. *Am J Gastroenterol* 2004; **99**: 57-63
 - 11 Fattovich G, Broilo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, Ruol A. Natural history and prognostic factors for chronic hepatitis type B. *Gut* 1991; **32**: 294-298
 - 12 Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. *Hepatology* 1988; **8**: 493-496
 - 13 Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. *Liver* 1989; **9**: 235-241
 - 14 Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, Krogsgaard K, Degos F, Carneiro de Moura M. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. *Hepatology* 1995; **21**: 77-82
 - 15 Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. *Clin Infect Dis* 2001; **33**: 403-405
 - 16 Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. *Scand J Gastroenterol* 2002; **37**: 366-369
 - 17 Kagawa T, Watanabe N, Kanouda H, Takayama I, Shiba T, Kanai T, Kawazoe K, Takashimizu S, Kumaki N, Shimamura K, Matsuzaki S, Mine T. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. *World J Gastroenterol* 2004; **10**: 1686-1687
 - 18 Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. *J Clin Microbiol* 1999; **37**: 310-314
 - 19 Hoofnagle JH, Minuk GY, Dusheiko GM, Schafer DF, Johnson R, Straus S, Jones EA, Gerin JL, Ishak K. Adenine arabinoside 5'-monophosphate treatment of chronic type B hepatitis. *Hepatology* 1982; **2**: 784-788
 - 20 Weller IV, Lok AS, Mindel A, Karayiannis P, Galpin S, Monjardino J, Sherlock S, Thomas HC. Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. *Gut* 1985; **26**: 745-751
 - 21 Marcellin P, Ouzan D, Degos F, Brechot C, Metman EH, Degott C, Chevalier M, Berthelot P, Trepo C, Benhamou JP. Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients. *Hepatology* 1989; **10**: 328-331
 - 22 Hoofnagle JH, Hanson RG, Minuk GY, Pappas SC, Schafer DF, Dusheiko GM, Straus SE, Popper H, Jones EA. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. *Gastroenterology* 1984; **86**: 150-157
 - 23 Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med* 1998; **339**: 61-68
 - 24 Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. *Gastroenterology* 2003; **124**: 105-117
 - 25 Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. *Gastroenterology* 2003; **125**: 1714-1722
 - 26 Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Watahiki S, Kumada H. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. *J Med Virol* 2006; **78**: 341-352
 - 27 Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. *J Med Virol* 1999; **59**: 270-276
 - 28 Natsuizaka M, Hige S, Ono Y, Ogawa K, Nakanishi M, Chuma M, Yoshida S, Asaka M. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region. *J Viral Hepat* 2005; **12**: 154-159
 - 29 Janssen HL, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S. Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep). *BMJ* 1993; **306**: 107-108
 - 30 Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. *Hepatology* 2000; **32**: 129-134
 - 31 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. *N Engl J Med* 2003; **348**: 800-807
 - 32 Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med* 2003; **348**: 808-816
 - 33 Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Kleszczewski KS, Thiry A, Rose RE, Colonna RJ, Hines RG. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. *Gastroenterology* 2005; **129**: 1198-1209
 - 34 Chang TT, Gish RG, de Man R, Gadanho A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonna R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2006; **354**: 1001-1010
 - 35 Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonna R, Fernandes L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med* 2006; **354**: 1011-1020
 - 36 van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, Wiedenmann B, Berg T. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. *Hepatology* 2004; **40**: 1421-1425
 - 37 van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. *J Viral Hepat* 2005; **12**: 364-372

S- Editor Wang GP L- Editor Wang XL E- Editor Lu W

Original Article

Amino acid substitutions in the S region of hepatitis B virus in sera from patients with acute hepatitis

Junko Aono,^{1,3} Hiroshi Yotsuyanagi,¹ Hideyuki Miyoshi,² Takeya Tsutsumi,¹ Hajime Fujie,² Yoshizumi Shintani,¹ Kyoji Moriya,¹ Chiaki Okuse,⁴ Michihiro Suzuki,⁴ Kiyomi Yasuda,⁵ Shiro Iino⁵ and Kazuhiko Koike¹

Departments of ¹Infectious Diseases and ²Gastroenterology, Internal Medicine, University of Tokyo, ³Center for Liver Diseases, Seizankai Kiyokawa Hospital, Tokyo, ⁴Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Chiba, ⁵Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

Background: An increase in the number of acute hepatitis patients with hepatitis B virus (HBV) of non-indigenous genotypes may reduce the efficacy of vaccination against HBV.

Methods: We have determined the amino acid (aa) sequences in the major hydrophilic region (MHR) in the S region of HBV in patients with acute hepatitis B and compared those with the ones from HBV strains used for the production of HBV vaccines commercially available in Japan.

Results: Of 48 patients studied, 11 were infected with genotype A, 11 with genotype B and 26 with genotype C HBV. The aa sequences of the nine genotype A isolates were the same as the aa sequence of J02205 which is used for the production of one of the commercially available recombinant vaccines. The aa sequences of the 11 genotype B isolates differed from the aa sequence of J02205 in two or three amino acids. Of the

26 genotype C isolates, 22 had the same aa sequence as X01587 which is used for the production of another recombinant vaccine. The remaining genotype C isolates had aa substitutions at aa131, which have a potential to alter the hydrophathy and the three-dimensional structure of the MHR. The differences among the three current HBV vaccines in aa sequences in the MHR theoretically alter the hydrophathy and three-dimensional structure.

Conclusion: Our results suggest that the transmission of HBV isolates with different genotypes or with aa substitutions in the MHR might reduce the efficacy of currently available HBV vaccines in the protection of HBV infections.

Key words: genotype, hepatitis B virus, major hydrophilic region, vaccine

INTRODUCTION

ABOUT 300 MILLION people in the world are chronically infected with hepatitis B virus (HBV). Chronic infection may eventually lead to liver cirrhosis or hepatocellular carcinoma.^{1–4} To prevent the transmission of this virus, vaccination has been introduced in many countries. Indeed, universal vaccination has not only reduced the number of infected individuals, but also the number of deaths related to HBV.^{5,6}

In Japan, in 1985, a national project was started to vaccinate children born to HBV-infected mothers. The chances of vertical transmission from HBV-carrying mothers have decreased. Recently, the prevalence of HBV in Japan has decreased to approximately 0.6%.⁷

Because the number of individuals infected with HBV has decreased, the number of patients with acute hepatitis B, mainly caused by horizontal transmission from HBV carriers, should also have decreased. However, in Japan, the number of patients with acute hepatitis B has recently increased (Yatsushashi H. *et al.*, 2004, unpubl. data).

The increase in the number of patients with acute hepatitis B may, in part, be the result of patients carrying novel HBV genotypes imported from abroad. For

Correspondence: Dr Hiroshi Yotsuyanagi, Department of Infectious Diseases, Internal Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-8655, Japan. Email: hyotsu-uky@umin.ac.jp
Received 20 September 2006; revision 31 January 2007; accepted 8 March 2007.

example, in recent years, genotype A HBV has often been detected in patients with acute hepatitis B.^{8,9}

Genotype A HBV is transmitted from individuals who live in or have immigrated from other countries to Japan. Its infection is characterized by a high viral load and a long hepatitis B surface antigen (HBsAg) positivity period. The transition of acute hepatitis B with genotype A HBV infection to the chronic state has been reported recently.^{8,10} Decreasing the transmission rate of genotype A HBV is therefore important for the control of the disease. Introducing universal vaccination for adolescents or adults is a measure to be considered.

The effectiveness of universal vaccination depends on the reactivity of vaccines against HBV. HBsAg binds antibody to hepatitis B surface antigen (anti-HBs) produced against HBV vaccines mainly via the 'a' determinant region (aa124–aa149). This region contains common antigenic epitopes of all subtypes (adw, adr, ayw, ayr) of HBsAg and lies in the major hydrophilic region (MHR) between aa99 and aa169. Amino acid (aa) substitutions in the MHR, particularly in the 'a' determinant region, can alter B cell epitopes of HBsAg, leading to immunological escape from the host immunity induced by either vaccination or previous infection.¹¹ Therefore, if HBV prevalent in Japan has aa substitutions in the MHR, the effect of universal vaccination may be reduced.

In Japan, three types of HBV vaccine (Bimmugen, The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan; Heptavax, Merck & Co., Whitehouse Station, NJ, USA; and Meinyu, Meiji Dairies, Tokyo, Japan) are now available. Efficacy and immunogenicity of vaccines are not always comparable or identical.^{12,13} Whether giving a single vaccine effectively prevents the transmission of all genotypes of HBV is an important but still unsolved problem. Elucidating the aa substitutions in the MHR may give a clue to this problem.

The purpose of the present study is to determine the difference of the aa sequences in the MHR of HBV among isolates from patients with acute hepatitis and also the difference of the aa sequences among viral strains used for the production of anti-HBV vaccines, and to find ways to use currently available vaccines as effective prophylaxes.

METHODS

Patients

FROM 1992 TO 2001, serum samples were collected from 48 patients diagnosed with acute hepatitis B in our institutions. Only patients whose serum samples

were stored at the onset of hepatitis were included in this study. All the 48 patients ran a self-limited clinical course. No patients subsequently developed fulminant hepatic failure or chronic sequelae.

The criteria for the diagnosis of acute hepatitis B were the following: (i) an acute onset of liver injury without a history of liver dysfunction and positivity for HBsAg in serum; and (ii) immunoglobulin M (IgM) antibody to HBV core antigen (anti-HBc) at a titer of more than 2.5 of cut-off index. Coinfection with a hepatitis A virus or a hepatitis C virus was excluded by serological tests. None of the patients had previously received any vaccination against HBV.

Serum samples from the 48 patients with acute hepatitis B were examined virologically, and the results were examined for correlations with clinical characteristics. Informed consent was obtained from each patient. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committees of our institutions.

Determination of HBV-DNA

Hepatitis B virus DNA level was determined using transcription-mediated amplification (TMA) and a hybridization protection assay (Chugai Diagnostics Science, Tokyo, Japan) using the protocol of Kamisango *et al.*¹⁴ The range of detection using TMA was from 3.7 log genome equivalents (LGE)/mL (i.e. $10^{3.7}$ copies/mL corresponding to 5000 copies/mL) to 8.7 LGE/mL ($10^{8.7}$ copies/mL). In seven of 34 studied serum samples, the level of HBV-DNA was lower than 3.7 LGE/mL and these were categorized as 3.7 LGE/mL.

Genotyping HBV

Hepatitis B virus genotypes were determined using commercial enzyme immunoassay kits (Smitest HBV Genotyping kit; Genome Science, Fukushima, Japan). In brief, DNA extracted from serum was amplified by polymerase chain reaction (PCR) using three sense primers (i.e. s1: 5'-ACCAACCTCTGGGATTCTTCC-3', s2: 5'-ACCAATCCTCTGGGATTCTTCCC-3', and s3: 5'-AGCAATCCTCTAGGATTCTTCC-3' [nt 2902–2924]) and an antisense primer (i.e. as1: 5'-GAGCCTGAGGGCTCCACCC-3' [nt 3091–3073]) biotinylated at the 5' end; their sequences were deduced from conserved sequences in the pre-S1 region of HBV. The biotin-labeled and amplified HBV-DNA was denatured in an alkaline solution, and tested for hybridization to probes specific for one of the seven HBV genotypes (A–G) immobilized on wells of a 96-well

microplate. Thereafter, hybridization was detected by staining with the streptavidin-horseradish peroxidase (HRP) conjugate.¹⁵

Amplifying and sequencing the S region of HBV-DNA

The entire aa sequence of MHR in the S region was amplified by two-stage PCR using genotype-specific primers. The outer primers for the amplification of the first fragment were 5'-TTTCCACCAAGCTCTGCAA-3' (sense: nt 9–28) and 5'-TTCAGGGAATAACCCCATCT-3' (antisense: nt 872–853) for genotype A, 5'-CTCCA CCACITTTCCA GACT-3' (sense: nt 1–22) and 5'-CAACTCCCAATTACATATCCC-3' (antisense: nt 899–879) for genotype B and 5'-TTACAGGCGGGG TTTTCTT-3' (sense: nt 70–89) and 5'-TACAGACTT GGCCCCAATA-3' (antisense: nt 771–752) for genotype C. The inner primers were 5'-AGAGTCAGGGGCC TGTATTTT-3' (sense: nt 35–55) and 5'-AGGGAATAA CCCCATCCTTT-3' (antisense: nt 869–849) for genotype A, 5'-TTCAAGATCCCAGAGTCAGG-3' (sense: nt 24–43) and 5'-AGGGAATATCCCCACCTTTT-3' (antisense: nt 869–849) for genotype B and 5'-CGGGGTT TCTTGTGACA-3' (sense: nt 77–97) and 5'-CCCAAT ACCACATCATCCATA-3' (antisense: nt 758–738) for genotype C.

The first stage of amplification was carried out in a thermal cycler for 40 cycles (94°C, 1 min; 55°C, 1 min; 72°C, 1 min) in 100 µL reaction mixture containing 200 mM dNTPs, 1.0 mM each of primers and PCR buffer (50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl₂ and 0.001% (wt/vol) gelatin) and 2 U Ampli-Taq polymerase (Perkin Elmer Cetus, Norwalk, CT, USA). PCR products (2 µL) were subjected to the second stage of amplification under the same conditions as those in the first stage. Standard precautions to avoid contamination were taken during PCR, with a negative control serum sample included in each run.

Amplification products were purified on Wizard PCR preps DNA purification resin (Promega, Madison, WI, USA), and sequenced bidirectionally with a Dye Terminator Cycle Sequencing Ready Reaction kit (PE Applied Biosystems, Foster City, CA, USA) using the above-mentioned PCR primers. Sequencing was performed in an automated DNA sequencer (ABI 377; PE Applied Biosystems).

The nucleotide sequences of HBV isolates from the patients were compared with those of three reference HBV strains which are used for vaccine production.^{16–18}

Phylogenetic trees were constructed with the Mega Program version 2.1 (Center for Evolutionary Functional Genomics, The Biodesign Institute, Tempe, AZ, USA) using the Kimura two-parameter matrix and the neighbor-joining method.¹⁹ To confirm the reliability of phylogenetic tree analysis, boot-strap resampling, and reconstruction were carried out 500 times.

Hydrophobicity and secondary structure analysis

The hydrophobicity profile of the MHR of the S region was predicted by computer-assisted Kyte-Doolittle analysis (an estimate of hydrophobicity based on the bulk phase partitioning of side chain hydrophobicity alone)²⁰ with GENETYX-MAC software (version 10.1; Software Development, Tokyo, Japan).

The secondary structures of the amino acids in the same region were predicted by computer-assisted Robson²¹ and Chou-Fasman analyses²² with the GENETYX-MAC software.

Statistical analyses

Data were analyzed by the chi-squared test for categorical data and Student's *t*-test or the Mann-Whitney *U*-test for continuous variables. *P*-values less than 0.05 were regarded as statistically significant.

RESULTS

Distribution and clinical characteristics of HBV genotypes

HEPATITIS B VIRUS genotype was determined in the 48 patients with acute hepatitis B. Genotype A was detected in 11 (23%) patients, genotype B in 11 (23%) and genotype C in 26 (54%).

The clinical and demographic backgrounds of the patients with acute hepatitis B who were infected with HBV of different genotypes are shown in Table 1. The mean ages of all the groups were similar. The proportion of male to female patients was higher in genotype A infection than in genotypes B or C infection (100%, 73% and 64%, respectively: A vs B, *P* = 0.22; A vs C, *P* = 0.01; B vs C, *P* = 0.16). The maximum alanine aminotransferase (ALT) levels were lower in patients with genotype A infection than in patients with genotypes B or C infection (1646 ± 1123, 3085 ± 1119 and 2545 ± 981 IU/L, respectively: A vs B, *P* = 0.01; A vs C, *P* = 0.03; B vs C, *P* = 0.89). The maximum HBV-DNA levels were not significantly different between the

Table 1 Demographic and clinical differences among patients with acute hepatitis infected with HBV of distinct genotypes

Features	Genotypes of HBV			Differences (<i>P</i> -value)		
	A (<i>n</i> = 11)	B (<i>n</i> = 11)	C (<i>n</i> = 26)	A vs B	A vs C	B vs C
Age (years)	30.6 ± 7.5	28.1 ± 5.1	31.1 ± 9.1	0.41	0.87	0.33
Gender (M:F)	11:0	8:3	15:11	0.22	0.01	0.16
ALT (IU/L)	1646 ± 1123	3085 ± 1119	2545 ± 981	0.01	0.03	0.89
HBV-DNA (LGE/mL)	6.8 ± 1.7	6.6 ± 2.1	5.2 ± 1.2	0.60	0.23	0.06

ALT, alanine aminotransferase; HBV, hepatitis B virus.

genotypes (6.8 ± 1.7, 6.6 ± 2.1 and 5.2 ± 1.2 LGE/mL, respectively: A vs B, *P* = 0.60; A vs C, *P* = 0.23; B vs C, *P* = 0.06).

Amino acid sequence of the S region

The aa sequence of the S region between aa27 and aa203 was determined in the 48 sequences. Figure 1 shows a phylogenetic tree constructed using the 48 sequences and 15 published sequences (four for genotype A, three for genotype B, three for genotype C, one for genotypes D, E, F, G and H). Among the 48 sequences we studied, 11 were classified into genotype A, 11 into genotype B and 26 into genotype C.

The aa sequence of the region between aa101 and aa163 including MHR (aa111-aa156) was compared among 48 sequences and three HBV sequences (X01587, J02205 and huGK-14) currently used for anti-HBV vaccine production. As shown in Figure 2, the aa sequences of X01587 (used for Bimmugen) and J02205 (used for Heptavax) differed in eight amino acids (i.e. aa110, aa113, aa114, aa126, aa131, aa143, aa160 and aa161). The aa sequence of huGK-14, which is used for the HBV-vaccine Meinyu, differed from that of X01587 in six amino acids and from that of J02205 in two amino acids.

Nine of the 11 isolates classified into genotype A had the same aa sequence as J02205. The remaining two isolates (AB289727 and AB289728) differed from J02205 at aa161 (Fig. 2).

Ten of the 11 isolates classified into genotype B had the same aa sequence as J02205 except for two amino acids (aa114 and aa131). The remaining isolate had another aa substitution at aa112 (Fig. 2).

As shown in Figure 2, 22 of the 26 isolates classified into genotype C had the same sequence as X01587. The remaining four isolates (from patients 10, 24, 30 and 48) had the same sequence as X01587 except for one aa substitution at aa131; the threonine (aa131) of X01587 was substituted with proline for three isolates

(AB289714, AB289720 and AB289736) and with alanine for one isolate (AB289701).

Hydrophobicity and secondary structure analysis

As mentioned above, the aa sequences of the MHR from four isolates differed from that of X01587 only at aa131. Furthermore, the aa sequence of the MHR differed between X01587 and J2205 in eight amino acids. We compared the hydrophobicity and secondary structure of the MHR among J02205, X01587 and two isolates with genotype C (one isolate with proline at aa131 and one with alanine at aa131). The results of Kyte-Doolittle hydrophobicity analysis based on the hydrophobicity index are shown in Figure 3. The substitution with alanine-131 was found to alter the patterns on the hydrophobicity plot, whereas the substitution with proline-131 was found to have little effect. A substitution with alanine-131 could increase the hydrophobicity of the first loop of the MHR, which may affect the antigenicity of HBV.

The secondary structure of our isolate with alanine-131 by Chou-Fasman analysis predicted an α -helix configuration for the region from aa126 to aa135 instead of the β -configuration predicted for the same region of X01587. The predicted secondary structure of our isolate with proline-131 coincided with that of X01587. In contrast, by Robson prediction, the secondary structure of our isolate with alanine-131 coincided with that of X01587; however, that of our isolate with proline-131 was found to have lost a turn structure between aa131 and aa134, which was predicted for X01587.

DISCUSSION

VACCINATION IS THE key to controlling HBV infection. In countries with a high prevalence of HBV infection, universal vaccination is effective not only for controlling viral infections but also for decreasing the incidence of hepatocellular carcinoma.^{5,23} Even in




Figure 1 Phylogenetic tree constructed using hepatitis B virus (HBV)-DNA sequences of the S gene. The sequences include four with genotype A, four with genotype B, three with genotype C, and those recovered from the serum of 48 patients with acute hepatitis B. J02205 (genotype A) is used for the production of Heptavax and X01587 (genotype C) is used for the production of Bimmugen. The horizontal bar indicates the number of nucleotide substitutions per site. Accession numbers are shown for the isolates that have been deposited in the DDBJ/EMBL/GenBank databases. The accession numbers for the HBV sequences from the 48 patients are also shown.




Figure 3 Hydropathy profile of the major hydrophilic region (MHR) of the S gene elaborated using the Kyte-Doolittle hydropathy index. Arrows show the positions of amino acids which are different among X01587, J02205, AB289701 (alanine-131) and AB289720 (proline-131). (a) X01587, (b) J02205, (c) AB289701 (alanine-131), (d) AB289720 (proline-131).

structure of the region. Therefore, the antibody produced against J02205 vaccines may not completely neutralize X01578 and vice versa. Indeed, previous studies showed that antibody profiles induced by recombinant vaccines produced from different genotypes are not identical with each other,¹² which suggests that antibodies produced by recombinant vaccines might not protect viral infection with different genotypes.

As shown in Figure 2, the aa sequences of our isolates classified into genotype A are very close to the aa sequence of J02205. Therefore, the transmission of genotype A HBV is prevented by Heptavax which is made from J02205.

The aa sequences of our isolates classified into genotype B are the same as the aa sequence of J02205 except for one substitution at aa131. This aa, which is asparagine and is located in the first stem loop structure of the MHR, was substituted with threonine in our genotype B isolates. Because asparagine and threonine have an uncharged side chain and similar polarity, genotype B HBV infection may be prevented effectively by Heptavax.

The aa sequences of our isolates classified into genotype C were the same as that of X01587 except for four isolates having a substitution at aa131. Bimmugen, which is produced from X01587, may be effective for

preventing genotype C HBV infections caused by those four isolates. However, Heptavax may not be effective for preventing genotype C HBV infection because of the difference in eight amino acids as described above.

The four isolates have proline or alanine instead of threonine-131, which has never been reported before. The polarities of threonine and proline/alanine are quite different. The Kyte-Doolittle hydropathy analysis suggests that substituting threonine at aa131 with alanine or proline would increase hydrophobicity, which may then lead to a change in antigenicity. Hou *et al.* reported that some blood donors who were tested negative for serum HBsAg had a substitution of isoleucine for threonine at aa131 in the S region.²⁴ They suggested that the structure and antigenicity of HBV may be altered by this substitution.

The secondary structure of our isolate with alanine-131 predicted by Chou-Fasman analysis suggested an α -helix configuration instead of a β -configuration in the region from aa126 to aa135. The secondary structure of our isolate with proline-131 predicted by Robson analysis suggested that this change causes the loss of a turn structure between aa131 and aa134. Some changes in the secondary structure can affect the three-dimensional structure of the protein and thus affect antigenicity. These results suggest that the transmission of the four

isolates with an aa substitution at aa131 may not be prevented by either Heptavax or Bimmugen.

However, the protective immunity elicited by HBV vaccines, which is usually polyclonal in nature, may not be totally lost or severely affected *in vivo* by the alteration of only a single amino acid in the 'a' determinant region.²⁵ Also, antibodies against regions outside the 'a' determinant region may be protective.²⁶ The protectivity of current vaccines may be elucidated by *in vitro* binding studies using polyclonal antibodies.

It was reported that some individuals immunized with recombinant vaccines are infected with HBV with or without mutations in the 'a' determinant region.^{11,27,28} HBV isolates with amino acid substitutions at aa144^{29–31} or 145^{11,27,28} are known to be transmitted despite vaccination. Indeed, some chronic HBV carriers are reported to have HBV with such amino acid substitutions.^{32,33} We were unable to find patients who had these substitutions in the present study. However, large-scale studies are necessary to elucidate the prevalence of 'vaccine-escape mutants' in patients with acute hepatitis B.

In conclusion, we have shown that the aa sequence of the MHR in the S gene of HBV is different among isolates from patients with acute HBV infection. Current vaccination may prevent the transmission of these HBV isolates, which should be further investigated.

ACKNOWLEDGMENT

WE THANK MS Yoriko Kajiki for her excellent technical assistance. We are grateful to doctors Kozo Ishidate and Yoshimasa Machida for helpful discussions. This work was supported in part by Health Sciences Research Grants from the Ministry of Health, Labor, and Welfare of Japan.

REFERENCES

- Manno M, Camma C, Schepis F *et al.* Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. *Gastroenterology* 2004; 127: 756–63.
- Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. *Liver* 1989; 9: 235–41.
- Fattovich G, Broilo L, Giustina G *et al.* Natural history and prognostic factors for chronic hepatitis type B. *Gut* 1991; 32: 294–8.
- Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. *Hepatology* 1988; 8: 493–6.
- Chang MH, Chen CJ, Lai MS *et al.* Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. *N Engl J Med* 1997; 336: 1855–9.
- Ni YH, Chang MH, Huang LM *et al.* Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. *Ann Intern Med* 2001; 135: 796–800.
- Tanaka J, Kumagai J, Katayama K *et al.* Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3 485 648 first-time blood donors during 1995–2000. *Intervirology* 2004; 47: 32–40.
- Kobayashi M, Suzuki F, Arase Y *et al.* Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. *J Gastroenterol* 2004; 39: 844–50.
- Yotsuyanagi H, Okuse C, Yasuda K *et al.* Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. *J Med Virol* 2005; 77: 39–46.
- Suzuki Y, Kobayashi M, Ikeda K *et al.* Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. *J Med Virol* 2005; 76: 33–9.
- Water JA, Kennedy M, Voet P *et al.* Loss of the common 'A' determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. *J Clin Invest* 1992; 90: 2543–7.
- Heijink RA, Schneeberger PM, Postma B, Crombach W. Anti-HBs levels after hepatitis B immunisation depend on test reagents: routinely determined 10 and 100 IU/L seroprotection levels unreliable. *Vaccine* 2002; 20: 2899–905.
- Hieu NT, Kim KH, Janowicz Z, Timmermans I. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. *Vaccine* 2002; 20: 1803–8.
- Kamisango K, Kamogawa C, Sumi M *et al.* Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. *J Clin Microbiol* 1999; 37: 310–14.
- Kato H, Orito E, Sugauchi F *et al.* Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. *J Virol Methods* 2003; 110: 29–35.
- Koike K, Yoshida E, Katagiri K *et al.* Production of hepatitis B virus surface antigen particles by the human hepatoma cell line huGK-14 in a serum-free medium. *Jpn J Cancer Res* 1987; 78: 1341–6.
- McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. *Nature* 1984; 307: 178–80.
- Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. *Nature* 1982; 298: 347–50.
- Sugita S, Yoshioka Y, Itamura S *et al.* Molecular evolution of hemagglutinin genes of H1N1 swine and human influenza A viruses. *J Mol Evol* 1991; 32: 16–23.

- 20 Kyte J, Doolittle F. A simple method for displaying the hydropathic character of a protein. *J Mol Biol* 1982; 157: 105-32.
- 21 Garnier J, Osguthorpe DJ, Robson B. Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. *J Mol Biol* 1978; 120: 97-120.
- 22 Chou PY, Fasman GD. Conformational parameters for amino acids in helical, β -sheet, and random coil regions calculated from proteins. *Biochemistry* 1974; 13: 211-12.
- 23 Ni YH, Chang MH, Huang LM *et al.* Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. *Ann Intern Med* 2001; 135: 796-80.
- 24 Hou J, Wang Z, Cheng J *et al.* Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. *Hepatology* 2001; 34: 1027-34.
- 25 Ogata N, Cote PJ, Zanetti AR *et al.* Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. *Hepatology* 1999; 30: 779-86.
- 26 Paulij WP, de Wit PL, Sunnen CM *et al.* Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen. *J Gen Virol* 1999; 80: 2121-6.
- 27 Carman WF, Zanetti AR, Karayiannis P *et al.* Vaccine-induced escape mutant of hepatitis B virus. *Lancet* 1990; 336: 325-9.
- 28 Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. *Lancet* 1995; 345: 1406-7.
- 29 Lee PI, Chang LY, Lee CY, Huang LM, Chang MH. Detection of hepatitis B surface gene mutation in carrier children with or without immunoprophylaxis at birth. *J Infect Dis* 1997; 176: 427-30.
- 30 Protzer-Knolle U, Naumann U, Bartenschlager R *et al.* Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. *Hepatology* 1998; 27: 254-63.
- 31 Shields PL, Owsianka A, Carman WF *et al.* Selection of hepatitis B surface 'escape' mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. *Gut* 1999; 45: 306-9.
- 32 Yamamoto K, Horikita M, Tsuda F *et al.* Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. *J Virol* 1994; 68: 2671-6.
- 33 Kato J, Hasegawa K, Torii N, Yamauchi K, Hayashi N. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. *Hepatology* 1996; 23: 389-95.

A Proteomics Method Revealing Disease-Related Proteins in Livers of Hepatitis-Infected Mouse Model

Tomoko Ichibangase,[†] Kyoji Moriya,[‡] Kazuhiko Koike,[‡] and Kazuhiro Imai^{*†}

Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi Tokyo, Japan 202-8585, and Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan 113-8655

Received February 19, 2007

In this post-genome era, a sensitive quantitative method is required for differential profiling analyses of clinical proteomes to understand the disease progress. Here, we adopt the FD-LC-MS/MS method, consisting of fluorogenic derivatization (FD), separation by liquid chromatography (LC), and identification by LC-tandem mass spectrometry (MS/MS), to reveal disease-related proteins in livers of hepatocarcinogenesis in transgenic (Tg) and non-transgenic (NTg) mice at three developmental stages. After 6 months, the expression of apoptosis-related proteins is suppressed. After 12 months, proteins related to respiration, the electron-transfer system, and anti-oxidation are significantly up-regulated. After 16 months, proteins related to defense, β -oxidation, and apoptosis are significantly suppressed. This fluctuating expression of proteins could explain the progression of hepatocarcinogenesis. The method would be useful for clinical proteomics analysis because of its high resolution, sensitivity, and reproducibility.

Keywords: DAABD-Cl • FD-LC-MS/MS method • core protein • hepatitis C • liver protein • fluorogenic derivatization

Introduction

Recent work in clinical proteomics has involved quantitative and comparative studies of mixture composition and/or the relative abundance of proteins under differing physiologically relevant conditions and differing experimental approaches, commonly referred to as differential profiling. Numerous approaches have been employed for protein quantification, including a one- or two-dimensional gel electrophoretic and liquid chromatographic (LC) method, followed by mass spectrometry (MS).¹⁻⁴ Each of the technical approaches has advantages and limitations. For example, gel-based methods are based on the densitometric quantification of proteins visualized using dyes on gel, followed by in-gel enzymatic digestion of the subject protein spots, with the resulting peptides then subjected to MS analysis. This approach has been widely practiced in proteomics studies because of its high resolution, which enables separating the protein isoforms and post-translational modifications. However, this method suffers from a lack of reproducibility, low sensitivity, low dynamic range, and difficulty in resolving proteins with extreme hydrophobicity or isoelectric points, among other issues.^{2,3,5,6} In recent years, the introduction of differential gel electrophoresis (DIGE) using fluorescence reagents such as CyDye DIGE Fluor minimal dye⁶⁻⁸ and saturation dye^{9,10} has somewhat improved the reproducibility, sensitivity, and dynamic range.

LC-based methods offer flexibility of choice over a wide range of stationary and mobile phases to resolve complex biological samples at the protein or peptide level. In these methods, proteins are usually digested into peptides prior to separation by separation columns. The advantage of this approach is that the resolved peptides from the column can be directly introduced into an MS system. To obtain high sensitivity and quantification, the stable-isotope labeling reagents, that is, the isotope-coded affinity tag (ICAT),¹¹ the cleavable ICAT (cICAT),^{3,12,13} and isobaric tags for relative and absolute quantitation (iTRAQ),^{3,14} were developed and have gained in popularity. However, a major disadvantage of these strategies is that the obtained peptides cannot be correctly identified as any given protein. Moreover, low-abundance peptides are masked by high-abundance peptides with similar m/z ratios. Thus, for highly complex samples, such as tissue homogenates, these methods are not suitable for the quantification of specific low-abundance proteins unless extensive purification is employed before analysis.^{2-4,12,13}

We recently reported a method for proteomics studies called the FD-LC-MS/MS method.¹⁵⁻¹⁸ This method involves fluorogenic derivatization (FD) of proteins using fluorogenic reagents such as 7-chloro-*N*-[2-(dimethylamino)ethyl]-2,1,3-benzoxadiazole-4-sulfonamide (DAABD-Cl), followed by HPLC separation of the derivatized proteins, isolation of the subject proteins, enzymatic digestion of the isolated proteins, and identification of the proteins utilizing HPLC and tandem MS with a database-searching algorithm. The FD-LC-MS/MS method has unique features, differing from other proteome approaches in using a fluorogenic reagent to derivatize proteins

* To whom correspondence should be addressed at 1-1-20 Shinmachi, Nishitokyo-shi Tokyo 202-8585, Japan. Tel. +81-42-468-9787. Fax: +81-42-468-9787. E-mail: k-imai@musashino-u.ac.jp.

[†] Musashino University.

[‡] University of Tokyo.




Figure 1. Chromatograms of proteins (8.0 μg protein) in mouse liver derivatized with DAABD-Cl. The chromatograms above and below were obtained from transgenic (12 months) and non-transgenic (12 months) mice, respectively. The altered peaks (106 proteins) between transgenic and non-transgenic mice were numbered, and as representatives, significantly altered peaks (15 proteins) and a peak (no. 53 for accuracy measurement) are described.

and HPLC to separate the derivatized proteins. The fluorogenic reagent is highly reactive and selective to thiols, is nonfluorescent itself, and is water-soluble, so there are few limitations to the complete derivatization of cysteine residues of proteins. The proposed method enables highly sensitive detection of derivatized proteins at the femtomol level,^{17,18} whereas other derivatized reagents, such as CyDye DIGE Fluoro minimal dye, would have difficulty forcing the labeling reaction into saturation.^{7,8} Separation by HPLC led to highly reproducible quantification. In addition, a protein can be isolated and identified from the corresponding peak fraction without losing any amino acid sequence information, including protein isoforms and post-translational modifications, because the isolated protein itself is digested into peptides following isolation by HPLC. Although this method has already identified more than 100 proteins in a soluble extract of *Caenorhabditis elegans*^{15–17} and has identified altered proteins in the islet of Langerhans in dexamethazone-treated rats,¹⁸ there have been no studies involving clinical proteomics analysis utilizing DAABD-Cl as a fluorogenic reagent. Therefore, we attempted to apply it to the quantification and differential profiling analysis of liver proteins taken from hepatitis C virus (HCV) core gene transgenic (Tg) and non-transgenic (NTg) as a model. HCV is the main cause of chronic hepatitis. Chronic hepatitis ultimately results in the progression of hepatocellular carcinoma (HCC). However, the mechanism of hepatocarcinogenesis associated with HCV infection is still unclear. K. Moriya et al. have suggested that the HCV core protein plays a critical role in the progression of HCC and that transgenic mice provide a good animal model for determining the molecular and pathological events in hepatocarcinogenesis with HCV infection.^{19–22} Such mice have been investigated previously in terms of morphological and biochemical changes in HCV infection, so far. Therefore, this study investigated the long-term consequences of HCV core

gene expression from the viewpoint of proteomics and evaluated the proposed method as the quantification and differential profiling analysis.

Materials and Methods

Transgenic Mice. The production of HCV core gene transgenic mice has been described.¹⁹ Because HCC develops preferentially in male transgenic mice, male mice were used for analysis. Male non-transgenic littermates were utilized as controls. At least three mice were used in each experiment, with the data then subjected to statistical analysis. In the previous studies,^{19,20} these transgenic mice developed hepatic steatosis, one of the characteristic histological features of chronic hepatic C, as early as 3 months of age. As the mice grew to 12 months of age, steatosis slowly progressed without neoplastic change. At the age of 16 months, one-fourth of the male mice had experienced hepatic tumors. Moreover, older transgenic mice (>12 months of age) morphologically exhibited an age-dependent increase in oxidative stress. Therefore, in this study, the transgenic and non-transgenic mice used were aged 6, 12, and 16 months, representing the early, medium, and late stages of hepatocarcinogenesis. Also, to exclude the influence of protein variations with advancing age, the amount of protein change due to HCV infection was calculated based on the Tg-to-NTg (Tg/NTg) ratio. All studies were performed according to the Helsinki Declaration and have passed our institutional review board.

Preparation of Sample and Determination of Total Proteins. Liver samples (100 mg) were homogenized in 500 μL of 10 mM CHAPS aq with a pestle on ice. The homogenate was centrifuged at 20 400g for 15 min at 4 $^{\circ}\text{C}$. The supernatant was then collected and stored as a soluble fraction at -20°C until use. The liver total proteins were determined with the Quick Start Bradford Protein assay kit (Bio-Rad Laboratories, Inc.) by following the written instructions. Bovine serum albumin was used as a protein standard.

FD and HPLC Conditions. The previous method¹⁶ was used for the FD procedure for liver proteins with DAABD-Cl, except that the borate buffer was replaced with a pH 8.7 buffer solution (6.0 M guanidine hydrochloride, Tokyo Chemical Industry). Briefly, homogenized liver tissue was diluted with the CHAPS aq to 4.0 mg/mL, and 10 μL of the sample was mixed with 60 μL of a mixture of 0.83 mM Tris (2-carboxyethyl) phosphine hydrochloride (TCEP), ethylenediamine-*N,N,N',N'*-tetraacetic acid sodium salt (Na_2EDTA), and 16.6 mM CHAPS in the pH 8.7 buffer solution; 25 μL of the buffer solution; and 5.0 μL of 140 mM DAABD-Cl in acetonitrile. After the reaction mixture was placed in a 40 $^{\circ}\text{C}$ water bath for 10 min, 3.0 μL of 20% trifluoroacetic acid (TFA) was added to stop the derivatization reaction. Twenty microliters of the reaction mixture (8.0 μg proteins) was injected into the HPLC system at a flow rate of 0.55 mL/min. The overall system consisted of a Hitachi L-7000 series HPLC system and a fluorescence detector (Jasco FP-2025 plus; λ_{ex} 395 nm; λ_{em} 505 nm). Since the derivatives offer adaptable selectivity for the stationary phase, a protein column (Intrada WP-RP, 250 \times 4.6 mm i.d., Imtakt Co.) with a column temperature of 60 $^{\circ}\text{C}$ was adopted to further improve the column separation. The mobile phases consisted of 0.15% TFA in acetonitrile/isopropanol/water (A) 9.0/1.0/90 and (B) 69/1.0/30. Mobile phase (C) was the same as (A), except with 0.20% TFA. The gradient condition was established with the following elution: 5.0% B and 1.0% C held for 5.0 min; to 30% B and 35% C in 30 min, and then held for 35 min; to 35% B and 35%

Table 1. Altered Proteins between Tg and NTg Mouse Livers for 6 Months^a

peak number	Tg/NTg ratio	protein name	molecular mass (Da)	GI number ^b
Down-Regulated marker				
54	0.55	Major urinary protein (MUP)	20680	gi 295910
56	0.64*	MUP	17549	gi 53271
58	0.58	MUP	17549	gi 53271
55	0.63	Glial fibrillary acidic protein	46498	gi 14193690
respiration				
52	0.52*	α -globin	15076	gi 49901
electron-transfer system				
57	0.64	ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit d	18752	gi 16741459
apoptosis				
1	0.54*	Eukaryotic translation elongation factor 1 α 1 (EF-1 α 1)	50140	gi 13278382
glycolytic system				
77	0.74	PREDICTED: similar to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)	35789	gi 51768209
other				
34	0.62	ND***		
Up-Regulated				
respiration				
27	1.28	α -globin	15076	gi 49900
29	1.28	α -globin	15076	gi 49900
37	1.35	α -globin	15076	gi 49900
defense				
44	1.14	Cu/Zn-superoxide dismutase (SOD)	15955	gi 201006
75	1.69	Glycine N-methyltransferase	32712	gi 15679953
78	1.22	Aldo-keto reductase family 1, member C6	37024	gi 13487925
79	1.32	Glutathione S-transferase, mu 1	25953	gi 61402231
95	1.29	Glutathione S-transferase, α 3	25344	gi 31981724
fatty acid metabolism (containing β-oxidation)				
35	1.43	Fatty acid-binding protein, hepatic (fragment)	10173	gi 90485
36	1.24	Fatty acid-binding protein, hepatic (fragment)	10173	gi 90485
42	1.37	Fatty acid-binding protein, hepatic (fragment)	10173	gi 90485
82	1.31	Acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase)	41831	gi 20810027
apoptosis				
3	2.21	EF-1 α 1	50140	gi 13278382
glycolytic system				
61	1.40	Fructose-bisphosphate aldolase B	39548	gi 15723269
99	1.36	Enolase 1, α non-neuron	47095	gi 12963491
metabolism				
68	1.37	Carbonic anhydrase 3	29348	gi 31982861
other				
26	1.41	Unnamed protein product	58587	gi 12852157
33	1.40	Unnamed protein product	57807, 58587,	gi 12852157, gi 26345440,
			57007, 52653	gi 2634914, gi 26349459
112	1.42	put. β -Actin (aa 27–375)	39161	gi 49868

^a Peak numbers correspond to those in Figure 1. Asterisks indicate significant differences (two-tailed Student's *t* test, * $P \leq 0.05$, ** $P \leq 0.01$). ***ND, not detected. ^b GI number is simply a series of digits that are assigned consecutively to each sequence record processed by NCBI. The GI system of sequence identifiers runs parallel to the accession.version system, which was implemented by GenBank, EMBL, and DDBJ in February 1999. Therefore, if the protein sequence changes in any way, it will receive a new GI number. (<http://www.ncbi.nlm.nih.gov/Sitemap/samplerecord.html#ProteinIDB>).

C in 70 min, then to 38% B and 35% C in 130 min; to 44% B and 55% C in 250 min, and then held for 50 min; to 47% B and 53% C in 330 min; to 60% B and 40% C in 480 min; to 70% B and 30% C in 520 min; and then to 90% B and 10% C in 570 min.

Because of the differential profiling of proteins in transgenic and non-transgenic mice, the corresponding peak heights in the different elution profiles were compared for each month age. The correspondence of the peak was judged not only from the specific retention time of the derivatives, but also confirmation of the protein following isolation and identification of the derivatives. The Tg/NTg ratio was also compared between three developmental stages to investigate the consequences of

HCV core gene expression during the progression of hepatocarcinogenesis.

Identification of Derivatized Proteins. Each eluate of the subject proteins was concentrated to 5.0 μ L under reduced pressure. The residue was diluted with 50 μ L of 50 mM ammonium bicarbonate solution (pH 7.8) containing 0.50 U trypsin and 10 mM calcium chloride, and the resultant mixture was incubated for 2.0 h at 37 °C. The peptide mixture (20 μ L) was directly subjected to a nanoLC-ESI-tandem MS spectrometer (HCT plus, Bruker Daltonics). Chromatography was performed using an Ultimate/Famos/Switchos suite of instruments (LC Packings, Dionex). The sample was loaded onto a nanocolumn (300 μ m i.d. \times 1.0 mm, C18 PepMap) in the

Table 2. Altered Proteins between Tg and NTg Mouse Livers for 12 Months^a

peak number	Tg/NTg ratio	protein name	molecular mass (Da)	GI number ^b
Down-Regulated				
respiration				
29	0.64	α -globin	15076	gi 49900
defense				
75	0.56	Glycine <i>N</i> -methyltransferase	32712	gi 15679953
76	0.72	Glutathione <i>S</i> -transferase, mu 1	25953	gi 61402231
91	0.79	Methionine adenosyltransferase I, α	43481	gi 19526790
fatty acid metabolism (containing β-oxidation)				
36	0.74	Fatty acid-binding protein, hepatic	10173	gi 90485
40	0.80	Fatty acid-binding protein, hepatic	10173	gi 90485
102	0.77	Peroxisomal acyl-CoA oxidase	74608	gi 2253380
metabolism				
68	0.75	Carbonic anhydrase 3	29348	gi 31982861
105	0.80	Aldehyde dehydrogenase family 1, subfamily A1	54447	gi 7304881
amino acid synthesis				
80	0.61	4-Hydroxyphenylpyruvate dioxygenase	45054	gi 849053
other				
106	0.68	Heat-responsive protein	18462	gi 1255116
Up-Regulated				
marker				
55	1.52	Glial fibrillary acidic protein	46498	gi 14193690
56	1.23	MUP	17549	gi 53271
58	1.68	MUP	17549	gi 53271
70	1.51	α -Fetoprotein	47195	gi 191765
respiration				
4	2.50	Hemoglobin, β adult major chain	15738	gi 31982300
66	1.45	Hemoglobin, β adult major chain	15738	gi 31982300
67	1.98*	Hemoglobin β	15653	gi 229301
27	2.27	α -globin	15076	gi 49900
28	2.43	α -globin	15076	gi 49900
30	1.70	α -globin	15076	gi 49901
31	1.64	α -globin	15076	gi 49900
51	2.12	α -globin	15076	gi 49900
53	2.05	α -globin	15076	gi 49902
electron-transfer system				
20	1.85*	ATP synthase, H ⁺ transporting, mitochondrial F1 complex, epsilon subunit	5834	gi 13385484
57	1.56*	ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit d	18752	gi 16741459
protein synthesis				
10	2.43	Ribosomal protein L28	15700	gi 56541228
46	2.33	Ribosomal protein S16	16319	gi 70920
defense				
9	1.80	SOD	15955	gi 201006
11	2.28	SOD	15752	gi 226471
15	1.24	SOD	15955	gi 201006
18	1.96	SOD	15955	gi 201006
44	1.85	SOD	15955	gi 201006
12	1.42	60S Ribosomal protein	24692	gi 899445
43	1.31	Thioredoxin 1	11668	gi 6755911
50	1.99	Chain C, Crystal Structure Of Macrophage Migration Inhibitory Factor	12365	gi 5542287
69	1.60	D-Dopachrome tautomerase	13069	gi 6753618
71	2.24	Albumin 1	68648	gi 19353306
73	2.11	Albumin 1	68648	gi 19353306
89	1.63	Albumin 1	68648	gi 19353306
83	1.47**	Betaine-homocysteine methyltransferase (BHMT)	44992	gi 62533211
90	2.17	Methionine adenosyltransferase I, α	43481	gi 19526790
100	1.25	Glycine <i>N</i> -methyltransferase	32712	gi 15679953
fatty acid metabolism (containing β-oxidation)				
7	1.95	3-Ketoacyl-CoA thiolase B	43968	gi 18043769
35	1.27	Fatty acid-binding protein, hepatic - (fragment)	10173	gi 90485
41	1.28	Fatty acid-binding protein, hepatic - (fragment)	10173	gi 90485
82	1.32	Acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase)	41831	gi 20810027
apoptosis				
1	2.86	EF-1 α 1	50139	gi 13278381
2	2.79	EF-1 α 1	50140	gi 13278382
3	1.64	EF-1 α 1	50140	gi 13278382
8	2.02	Ribosomal protein S29, isoform 1	6672	gi 22267962
24	2.06	Ribosomal protein L14	23549	gi 13385472

Table 2. (Continued)

peak number	Tg/NTg ratio	protein name	molecular mass (Da)	GI number ^b
glycolytic system				
59	2.96	Fructose-bisphosphate aldolase B	39548	gi 15723268
62	1.21	Fructose-bisphosphate aldolase B	39548	gi 15723268
77	1.39	PREDICTED: similar to GAPDH	35789	gi 51768209
112	1.64	Lactate dehydrogenase 1, A chain	36475	gi 6754524
metabolism				
21	1.79	TI-225	14167	gi 1167510
22	2.02	TI-225	14167	gi 1167510
32	2.02	Cystatin B	11039	gi 6681071
72	3.23	Carbonic anhydrase 3	29348	gi 31982861
104	1.83*	Acetaldehyde dehydrogenase (ALDH)	54410	gi 9755362
110	1.82	Aldh2 protein	56502	gi 13529509
115	1.90	Malate dehydrogenase (EC 1.1.1.37)	31692	gi 164543
116	2.10	Argininosuccinate lyase	51707	gi 19526986
signal transduction				
47	1.70	Phosphatidylethanolamine binding protein	20847	gi 9256572
amino acid synthesis				
74	2.21	Glycine- <i>N</i> -acyltransferase	34076	gi 22122359
other				
5	2.02	ND***		
6	1.99	ND***		
118	1.97	ND***		
19	3.56	γ -actin	40992	gi 809561
23	1.40*	Diazepam binding inhibitor, splice form 1b	15219	gi 67511482
39	2.80	Saposin	61353	gi 249387
45	2.13	Unnamed protein product	58587, 57007, 52653, 49471	gi 12852157, gi 26345440, gi 26349141, gi 26349459,
49	1.42	Peptidylprolyl isomerase A	17960	gi 71051228
103	1.53*	Sorbitol dehydrogenase precursor	40066	gi 1009706
117	3.03	Unnamed protein product	57614	gi 52787

^a Peak numbers correspond to those in Figure 1. Asterisks indicate significant differences (two-tailed Student's *t* test, **P* ≤ 0.05, ** *P* ≤ 0.01). ***ND, not detected. ^b GI number is simply a series of digits that are assigned consecutively to each sequence record processed by NCBI. The GI system of sequence identifiers runs parallel to the accession.version system, which was implemented by GenBank, EMBL, and DDBJ in February 1999. Therefore, if the protein sequence changes in any way, it will receive a new GI number. (<http://www.ncbi.nlm.nih.gov/Sitemap/samplerecord.html#ProteinIDB>).

injection loop, and washed using 0.10% TFA in 2.0% acetonitrile at 30 μ L/min using the Switchos pump. Peptides were then separated on a nanoflow column (75 μ m i.d. \times 15 cm, C18 PepMap) at a flow rate of 170 μ L/min, employing a gradient from 5.0% to 60% buffer B (0.10% formic acid in 80% acetonitrile) over a period of 35 min (A buffer: 0.10% formic acid in 2.0% acetonitrile). One-second MS/MS scans were performed on each precursor ion. Ions observed with *m/z* between 350 and 1250 were fragmented with capillary energies from 1300 to 1800 V. The proteins were identified in accord with the previous method.^{15,17} There were several candidates with the same score for the unnamed protein products (peak numbers 33 and 45).

Statistical Analysis. Results are expressed as the mean \pm SD. The significance of the difference in means was determined by a two-tailed Student's *t* test.

Results and Discussion

Validation of The FD-LC-MS/MS Method. With the FD-LC-MS/MS method, more than 500 peaks were obtained from an extract of mouse liver tissue derivatized with DAABD-Cl. Typical chromatograms derived from transgenic and non-transgenic mice are depicted in Figure 1. Only the proteins which expression was estimated to fluctuate between transgenic and non-transgenic mice on the same months were identified after isolation, tryptic digestion, and LC-MS/MS identification of arbitrarily selected peak fractions (113 proteins). As a result,

106 proteins differed between transgenic and non-transgenic mice from 6 to 16 months of age, as summarized in Tables 1–3. The total protein amount required for quantification and identification was only 8.0 μ g per injection, and identification of even low-abundance proteins was possible with 40 μ g of total protein per injection into an HPLC column. In general, proteome analysis of biological samples labeled with CyDye, ICAT, cICAT, or iTRAQ requires from dozens to hundreds of micrograms of protein samples.^{3,7–10,11,13,14,28} The accuracy of the method was acquired based on the reproducibility of the peak heights using peaks 53, 83, and 32 as representatives of the high, medium, and low peaks obtained from each individual mouse. The relative standard deviation (RSD, %) for each between-day peak was less than 16 (high peak), 17 (medium peak), and 23% (low peak) (*n* = 3). The reproducibility of the retention time was also calculated using peak 32. The between-day RSD was 0.41% (*n* = 3). As an additional benefit, the simple apparatus, consisting of a pump, a column, and a fluorescence detector, does not require a complex facility for operation. In this study, we attempted a comprehensive profiling analysis of an 11-h operation to evaluate the utility of the method. After the elution time of a subject protein has been determined, it will be possible to reduce the analysis time for an arbitrary analysis of the subject protein by re-optimizing the separation conditions. It would also be possible to reduce the overall analysis time if we could develop a higher-performance column.

Table 3. Altered Proteins between Tg and NTg Mouse Livers for 16 Months^a

peak number	Tg/NTg ratio	protein name	molecular mass (Da)	GI number ^b
Down-Regulated				
respiration				
4	0.41	Hemoglobin, β adult major chain	15738	gi 31982300
67	0.69	Hemoglobin β	15653	gi 229301
53	0.70	α -globin	15076	gi 49902
108	0.70	Quinoid dihydropteridine reductase	25554	gi 21312520
protein synthesis				
101	0.54	Regucalcin	33385	gi 6677739
defense				
16	0.69	SOD	15955	gi 201006
65	0.64	Manganese superoxide dismutase	24662	gi 53450
40	0.53	Thioredoxin 1	11668	gi 6755911
63	0.72	Glutathione peroxidase (GSHPx-1) (Cellular glutathione peroxidase)	22268	gi 121666
75	0.49*	Glycine <i>N</i> -methyltransferase	32712	gi 15679953
79	0.61	Glutathione <i>S</i> -transferase, μ 1	25953	gi 61402231
83	0.69	BHMT	44992	gi 62533211
95	0.61	Glutathione <i>S</i> -transferase, α 3	25344	gi 31981724
97	0.51	Chain B, Glutathione <i>S</i> -Transferase Yfyf Cys 47-Carboxymethylated Class Pi, Free Enzyme	23350	gi 2624496
fatty acid metabolism (containing β-oxidation)				
36	0.69	Fatty acid-binding protein, hepatic (fragment)	10173	gi 90485
82	0.58	Acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase)	41831	gi 20810027
107	0.70	Acetyl-Coenzyme A acyltransferase 1	43926	gi 18700004
85	0.32*	Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), β subunit (HADHB)	51353	gi 13542763
102	0.58	Peroxisomal acyl-CoA oxidase	74608	gi 2253380
apoptosis				
3	0.69	Eukaryotic translation elongation factor 1 α 1	50140	gi 13278382
8	0.58*	Ribosomal protein S29, isoform 1	6672	gi 22267962
glycolytic system				
61	0.79	Fructose-bisphosphate aldolase B	39548	gi 15723269
98	0.42	Enolase 1, α non-neuron	47095	gi 12963491
99	0.58	Enolase 1, α non-neuron	47095	gi 12963491
metabolism				
32	0.46**	Cystatin B	11039	gi 6681071
68	0.80	Carbonic anhydrase 3	29348	gi 31982861
72	0.53	Carbonic anhydrase 3	29348	gi 31982861
109	0.30**	PREDICTED: Carbamoyl-phosphate synthetase 1 (CPS1)	165705	gi 51705066
84	0.50	Argininosuccinate synthetase	46555	gi 6996911
signal transduction				
87	0.65	Electron transferring flavoprotein, α polypeptide	35018	gi 13097375
amino acid synthesis				
80	0.39	4-Hydroxyphenylpyruvate dioxygenase	45054	gi 849053
other				
38	0.54	Histidine triad nucleotide binding protein 1	13768	gi 33468857
49	0.71	Peptidylprolyl isomerase A	17960	gi 71051228
64	0.69	Nit protein 2	30483	gi 12963555
86	0.64	γ -actin	40992	gi 809561
96	0.50	Unknown (protein for IMAGE:6414729)	50209	gi 53734652
103	0.70	Sorbitol dehydrogenase precursor	40066	gi 1009706
106	0.68	Heat-responsive protein	18462	gi 1255116
48	0.59	Unnamed protein product	65586	gi 12859782
Up-Regulated				
respiration				
37	1.33	α -globin	15076	gi 49900
fatty acid metabolism (containing β-oxidation)				
35	1.60	Fatty acid-binding protein, hepatic (fragment)	10173	gi 90485
other				
17	1.30	ND***		
33	1.34	Unnamed protein product	57807, 58587, 57007, 52653	gi 12852157, gi 26345440, gi 2634914, gi 26349459

^a Peak numbers correspond to those in Figure 1. Asterisks indicate significant differences (two-tailed Student's *t* test, **P* \leq 0.05, ***P* \leq 0.01). ***ND, not detected. ^b GI number is simply a series of digits that are assigned consecutively to each sequence record processed by NCBI. The GI system of sequence identifiers runs parallel to the accession.version system, which was implemented by GenBank, EMBL, and DDBJ in February 1999. Therefore, if the protein sequence changes in any way, it will receive a new GI number. (<http://www.ncbi.nlm.nih.gov/Sitemap/samplerecord.html#ProteinIDB>).

Differential Profiling. Differential profiling analysis was performed using liver tissue from HCV core gene transgenic and non-transgenic mice as model samples to evaluate the feasibility of the FD-LC-MS/MS method for clinical proteomics. To investigate the differential expression of proteins in transgenic and non-transgenic mice, the heights of the peaks corresponding to specific retention times were compared for each month of age, with 106 altered proteins observed. The differentially expressed proteins were classified by age, regulation and function (see Tables 1–3). Tg/NTg ratios over 1.2 were defined as up-regulated, and those below 0.8 were defined as down-regulated. Many proteins were up- or down-regulated during the progression of HCV-associated liver disease. Fifteen proteins were significantly altered in their levels of protein contents (Figure 2). At the age of 6 months, there were fewer down-regulated proteins than up-regulated (9 vs 19 proteins). In contrast, many kinds of proteins were different between transgenic- and non-transgenic mice at 12 months, with 11 proteins being down-regulated and 65 being up-regulated. At 16 months, there were more down-regulated proteins than in any other months (39 proteins), but only a small minority (four) of proteins were up-regulated.

The remarkable decrease in major urinary protein (MUP) and eukaryotic translation elongation factor 1 α 1 (EF-1 α 1) seen in Figure 2a represents an early event in the progression of HCV-associated liver disease (at 6 months). MUP has been known as a negative tumor marker.²³ Suppression of EF-1 α 1 expression prevents the induction of apoptosis, with the regulation reflected in an antiapoptotic mode.²⁴ Although one of the α -globin peaks (peak no. 52) decreased significantly, the other three peaks of α -globin (peak nos. 27, 29, and 37) tended to increase (see Table 1). The expression of α -globin has been shown to be up-regulated in apoptotic stimuli.²⁵ Therefore, the phenomenon might be considered a trend in apoptosis at this stage. Another observation made at the age of 6 months was the up-regulation of enzymes related to β -oxidation.

At 12 months of age, proteins related to respiration, the electron-transfer system, and defense against reactive oxygen species (ROS) were significantly up-regulated (Figure 2b). Moreover, a majority of proteins involved in respiration, protein synthesis, defense, apoptosis, the glycolytic system, and metabolism were more up-regulated than the changes observed at 6 months (Table 2).

Finally, at 16 months, proteins related to defense, β -oxidation, and apoptosis significantly decreased. Cystatin B²⁶ and carbamoyl-phosphate synthetase 1 (CPS1)²⁷ are known to be down-regulated in tumor and/or carcinoma and exhibited a significant decrease with the proposed method (Figure 2c). It was also established that various biological functions such as respiration, protein synthesis, defense, and metabolism tended to decline (Table 3).

As a whole, the investigation of the differential expression of proteins in transgenic and non-transgenic mice revealed that many proteins related to biological functions such as respiration, protein synthesis, defense, β -oxidation, and apoptosis fluctuate during the progression of chronic hepatitis C. These changes may reflect a gross effect derived from the loss of liver function in the various stages of chronic hepatitis in HCV infection.

Additionally, these data support, from the viewpoint of proteomics, the former results obtained from morphological and biochemical observation.^{19–21} For example, previous reports suggested that HCV core protein might affect a specific

pathway in the lipid metabolism.^{19,21} In fact, the core protein has a specific effect on lipid metabolism; fat droplets are formed and accumulate in the liver, leading to steatosis. An analysis of the composition of these lipid droplets determined that the concentration of carbon 18 monosaturated (C18:1) fatty acids, such as oleic and vaccenic acid, significantly increased in the livers of transgenic mice as well as in chronic hepatitis C patients.²¹ In the present study, hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein) β subunit (HADHB), which catalyzes fatty-acid metabolism, significantly decreased after 16 months (Figure 2). However, at 12 months, other enzymes associated with β -oxidation tended to increase (Table 2: peak nos. 7 and 82). In addition, up-regulation of ATP synthase led to an increase in the synthesis and metabolism of fatty acid at 12 months (Figure 2). Furthermore, acetaldehyde dehydrogenase (ALDH), which catalyzes the acetaldehyde metabolism, tended to be up-regulated in the same month (Figure 2). The metabolic reactions of fatty acid and acetaldehyde generate NADH₂⁺, and the overexpression then causes suppression of both metabolisms. Hence, these results suggest that the fatty-acid metabolism may become milder and resulted from the multiple protein changes related to β -oxidation, ATP synthase, and acetaldehyde metabolism with the progression of HCV-associated liver disease.

Previous reports also suggested that HCV core protein might alter the oxidant/antioxidant state in the liver.²⁰ The reports demonstrated that there is no significant difference in the levels of lipid peroxidation at 3 and 12 months of age, resulting in cellular and tissue damage by ROS. In contrast, after 16 months, the peroxidation and hydrogen peroxide levels increased remarkably and the levels of total and reduced glutathione, which plays an important role as an antioxidant, decreased. While, our results demonstrate that enzymes related to the antioxidant effect, such as betaine-homocysteine methyltransferase (BHMT) and Cu/Zn-superoxide dismutase (SOD), were up-regulated in transgenic mice at 12 months (Table 2: defense). Subsequently, up to 16 months, a decrease in BHMT and glycine *N*-methyltransferase related to the methylation cycle was observed (Figure 2). The decrease in these enzymes led to a deficiency of adenosylmethionine, impairing mitochondrial function and generating oxidative stress in the liver.^{29,30} It has recently been shown that a chronic deficiency of adenosylmethionine in the liver results in the spontaneous progression of steatohepatitis and HCC.³¹ In addition, the down-regulation of glycine *N*-methyltransferase would inhibit the synthesis of glutathione resulting in a shift to the oxidizing state, thereby reducing cell proliferation and increasing apoptosis.³² Therefore, the observed expression of antioxidants might reflect direct oxidative stress status; although at 12 months the up-regulated antioxidants protected against oxidative stress, the oxidative stress might become dominant by the deficiency of antioxidants among the progression of liver disease. Also, these results, derived from both studies, strongly suggest that HCV core protein induces ROS in an age-dependent manner. After 16 months, a biochemical²⁰ and proteomic analysis revealed a lack of glutathione, suggesting that supplying glutathione might be more effective than SOD in the progression of HCC in the late stage. Although a further animal experiment should be required for reliable clarification of the hepatocarcinogenesis mechanism, the proposed method was demonstrated to be extremely




Figure 2. Comparison of peak heights between transgenic (Tg; gray bar) and non-transgenic (NTg; white bar) mice, and the Tg-to-NTg ratio (open circle) from 6 months (6M) to 16 months (16M). Significantly altered proteins are seen at 6M (a), 12M (b), and 16M (c). Peak numbers correspond to those in Figure 1. Mean values \pm SD are plotted. Asterisks indicate significant differences (two-tailed Student's *t* test of all data points, **P* \leq 0.05, ***P* \leq 0.01).

useful for understanding biotransformation from the viewpoint of proteomics. Also, the data obtained in this experiment could support the understanding of hepatocarcinogenesis with HCV infection in terms of proteomics in addition to the morphological and biochemical observations mentioned above.

Conclusions

The proposed method demonstrated for the first time the existence of several event-marker proteins at the three progression stages of hepatocarcinogenesis in transgenic mice. It should be stressed that the FD-LC-MS/MS method would also

be worthwhile for clinical proteomics analysis, as a supplement to gel- and LC-based methods.

Acknowledgment. We thank Mr. Itaru Yazawa, Imtakt Co., for supplying Intradra WP-RP and Cadenza CL-C18 columns. Part of the work was supported by MEXT-HAITEKU (2004–2008).

References

- Romijn, E. P.; Krijgsveld, J.; Heck, A. J. R. Recent liquid chromatographic-(tandem) mass spectrometric applications in proteomics. *J. Chromatogr., A* 2003, 1000 (1–2), 589–608.
- Figey, D. Proteomics in 2002: A year of technical development and wide-ranging applications. *Anal. Chem.* 2003, 75 (12), 2891–2905.
- Wu, W. W.; Wang, G.; Baek, S. J.; Shen, R. F. Comparative study of three proteomic quantitative methods, DIGE, cIAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. *J. Proteome Res.* 2006, 5 (3), 651–658.
- Alaoui-jamali, M. A.; Xu, Y. Proteomic technology for biomarker profiling in cancer: an update. *J Zhejiang Univ. Sci. B* 2006, 7 (6), 411–420.
- Fountoulakis, M.; Suter, L. Proteomic analysis of the rat liver. *J. Chromatogr., B* 2002, 782, 197–218.
- Yokoyama, Y.; Kuramitsu, Y.; Takashima, M.; Iizuka, N.; Toda, T.; Terai, S.; Sakaida, I.; Oka, M.; Nakamura, K.; Okita, K. Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. *Proteomics* 2004, 4 (7), 2111–2116.
- Chromy, B. A.; Gonzales, A. D.; Perkins, J.; Choi, M. W.; Corzett, M. H.; Chang, B. C.; Corzett, C. H.; McCutchen-Maloney, S. L. Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. *J. Proteome Res.* 2004, 3 (6), 1120–1127.
- Unlu, M.; Morgan, M. E.; Minden, J. S. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. *Electrophoresis* 1997, 18 (11), 2071–2077.
- Fujii, K.; Kondo, T.; Yokoo, H.; Okano, T.; Yamada, M.; Yamada, T.; Iwatsuki, K.; Hirohashi, S. Database of two-dimensional polyacrylamide gel electrophoresis of proteins labeled with CyDye DIGE Fluor saturation dye. *Proteomics* 2006, 6 (5), 1640–1653.
- Shaw, J.; Rowlinson, R.; Nickson, J.; Stone, T.; Sweet, A.; Williams, K.; Tonge, R. Evaluation of saturation labelling two-dimensional difference gel electrophoresis fluorescent dyes. *Proteomics* 2003, 3 (7), 1181–1195.
- Welch, K. D.; Wen, B.; Goodlett, D. R.; Yi, E. C.; Lee, H.; Reilly, T. P.; Nelson, S. D.; Pohl, L. R. Proteomic identification of potential susceptibility factors in drug-induced liver disease. *Chem. Res. Toxicol.* 2005, 18 (6), 924–933.
- Hansen, K. C.; Schmitt-Ulms, G.; Chalkley, R. J.; Hirsch, J.; Baldwin, M. A.; Burlingame, A. L. Mass spectrometric analysis of protein mixtures at low levels using cleavable ¹³C-isotope-coded affinity tag and multidimensional chromatography. *Mol. Cell. Proteomics* 2003, 2 (5) 299–314.
- Qu, J.; Jusko, W. J.; Straubinger, R. M. Utility of cleavable isotope-coded affinity-tagged reagents for quantification of low-copy proteins induced by methylprednisolone using lipid chromatography/tandem mass spectrometry. *Anal. Chem.* 2006, 78 (13), 4543–4552.
- Hirsch, J.; Hansen, K. C.; Choi, S.; Noh, J.; Hirose, R.; Roberts, J. P.; Matthay, M. A.; Burlingame, A. L.; Maher, J. J.; Niemann, C. U. Warm ischemia-induced alterations in oxidative and inflammatory proteins in hepatic kupffer cells in rats. *Mol. Cell. Proteomics* 2006, 5 (6), 979–986.
- Masuda, M.; Saimaru, H.; Takamura, N.; Imai, K. An improved method for proteomics studies in *C. elegans* by fluorogenic derivatization, HPLC isolation, enzymatic digestion and liquid chromatography-tandem mass spectrometric identification. *Biomed. Chromatogr.* 2005, 19 (7), 556–560.
- Asamoto, H.; Ichibangase, T.; Saimaru, H.; Uchikura, K.; Imai, K. Existence of low molecular weight thiols in *Caenorhabditis elegans* demonstrated by HPLC-fluorescence detection utilizing 7-chloro-N-[2-(dimethylamino)ethyl]-2,1,3-benzoxadiazole-4-sulfonamide (DAABD-Cl). *Biomed. Chromatogr.* In press.
- Masuda, M.; Toriumi, C.; Santa, T.; Imai, K. Fluorogenic derivatization reagents suitable for isolation and identification of cysteine-containing proteins utilizing high-performance liquid chromatography-tandem mass spectrometry. *Anal. Chem.* 2004, 76 (3), 728–735.
- Toriumi, C.; Imai, K. An identification method for altered proteins in tissues utilizing fluorescence derivatization, liquid chromatography, tandem mass spectrometry, and a database searching algorithm. *Anal. Chem.* 2003, 75 (15), 3725–3730.
- Moriya, K.; Yotsuyanagi, H.; Shintani, Y.; Fujie, H.; Ishibashi, K.; Matsuura, Y.; Miyamura, T.; Koike, K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. *J. Gen. Virol.* 1997, 78 (7), 1527–1531.
- Moriya, K.; Nakagawa, K.; Santa, T.; Shintani, Y.; Fujie, H.; Miyoshi, H.; Tsutsumi, T.; Miyazawa, T.; Ishibashi, K.; Horie, T.; Imai, K.; Todoroki, T.; Kimura, S.; Koike, K. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. *Cancer Res.* 2001, 61 (11), 4365–4370.
- Moriya, K.; Todoroki, T.; Tsutsumi, T.; Fujie, H.; Shintani, Y.; Miyoshi, H.; Ishibashi, K.; Takayama, T.; Makuuchi, M.; Watanabe, K.; Miyamura, T.; Kimura, S.; Koike, K. Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. *Biochem. Biophys. Res. Commun.* 2001, 281 (5), 1207–1212.
- Moriya, K.; Fujie, H.; Shintani, Y.; Yotsuyanagi, H.; Tsutsumi, T.; Ishibashi, K.; Matsuura, Y.; Kimura, S.; Miyamura, T.; Koike, K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat. Med.* 1998, 4 (9), 1065–1067.
- Dragani, T. A.; Manenti, G.; Sacchi, M. R. M.; Colombo, B. M.; Della, P. G. Major urinary protein as a negative tumor marker in mouse hepatocarcinogenesis. *Mol. Carcinog.* 1989, 2 (6), 355–360.
- Ejiri, S. Moonlighting functions of polypeptide elongation factor 1: From actin bundling to zinc finger protein R1-associated nuclear localization. *Biosci. Biotechnol. Biochem.* 2002, 66 (1), 1–21.
- Brecht, K.; Simonen, M.; Heim, J. Upregulation of alpha globin promotes apoptotic cell death in the hematopoietic cell line FL5.12. *Apoptosis* 2005, 10 (5), 1043–1062.
- Shiraishi, T.; Mori, M.; Tanaka, S.; Sugimachi, K.; Akiyoshi, T. Identification of cystatin B in human esophageal carcinoma, using differential displays in which the gene expression is related to lymph-node metastasis. *Int. J. Cancer.* 1998, 79 (2), 175–178.
- Wu, S.; Li, S.; Zhang, H.; Luo, J.; Yu, Y. Cloning of cDNA coding for carbamoyl phosphate synthetase I and changes in levels of CPS1 mRNA during hepatocarcinogenesis. *Sci. Sin., Ser. B* 1988, 31 (2), 197–203.
- Wilson, K. E.; Marouga, R.; Prime, J. E.; Pashby, D. P.; Orange, P. R.; Crosier, S.; Keith, A. B.; Lathe, R.; Mullins, J.; Estibeiro, P.; Bergling, H.; Hawkins, E.; Morris, C. M. Comparative proteomic analysis using samples obtained with laser microdissection and saturation dye labelling. *Proteomics* 2005, 5 (15), 3851–3858.
- Liang, C. R. M. Y.; Leow, C. K.; Neo, J. C. H.; Tan, G. S.; Lo, S. L.; Lim, J. W. E.; Seow, T. K.; Lai, P. B. S.; Chung, M. C. M. Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. *Proteomics* 2005, 5 (8), 2258–2271.
- Heil, S. G.; Lievers, K. J.; Boers, G. H.; Verhoef, P.; Den-Heijer, M.; Trijbels, F. J.; Blom, H. J. Betaine-homocysteine methyltransferase (BHMT): Genomic sequencing and relevance to hyperhomocysteinemia and vascular disease in humans. *Mol. Genet. Metab.* 2000, 71 (3), 511–519.
- Santamaria, E.; Avila, M. A.; Latasa, M. U.; Rubio, A.; Martin-Duce, A.; Lu, S. C.; Mato, J. M.; Corrales, F. J. From the cover: Functional proteomics of nonalcoholic steatohepatitis: Mitochondrial proteins as targets of S-adenosylmethionine. *Proc. Natl. Acad. Sci. U.S.A.* 2003, 100 (6), 3065–3070.
- Wu, G.; Fang, Y. Z.; Yang, S.; Lupton, J. R.; Turner, N. D. Glutathione metabolism and its implications for health. *J. Nutr.* 2004, 134 (3), 489–492.

PR070094C